These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Nonhuman primate models of Parkinson's disease. Emborg ME ILAR J; 2007; 48(4):339-55. PubMed ID: 17712221 [TBL] [Abstract][Full Text] [Related]
4. Methodological Rigor in Preclinical Cardiovascular Studies: Targets to Enhance Reproducibility and Promote Research Translation. Ramirez FD; Motazedian P; Jung RG; Di Santo P; MacDonald ZD; Moreland R; Simard T; Clancy AA; Russo JJ; Welch VA; Wells GA; Hibbert B Circ Res; 2017 Jun; 120(12):1916-1926. PubMed ID: 28373349 [TBL] [Abstract][Full Text] [Related]
5. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. During MJ; Kaplitt MG; Stern MB; Eidelberg D Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246 [TBL] [Abstract][Full Text] [Related]
6. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
8. Symptomatic Models of Parkinson's Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. Johnston TM; Fox SH Curr Top Behav Neurosci; 2015; 22():221-35. PubMed ID: 25158623 [TBL] [Abstract][Full Text] [Related]
9. Investigating trial design variability in trials of disease-modifying therapies in Parkinson's disease: a scoping review protocol. Zeissler ML; Boey T; Chapman D; Rafaloff G; Dominey T; Raphael KG; Buff S; Pai HV; King E; Sharpe P; O'Brien F; Carroll CB BMJ Open; 2023 Dec; 13(12):e071641. PubMed ID: 38070893 [TBL] [Abstract][Full Text] [Related]
10. Trial designs used to study neuroprotective therapy in Parkinson's disease. Lang AE; Melamed E; Poewe W; Rascol O Mov Disord; 2013 Jan; 28(1):86-95. PubMed ID: 22927060 [TBL] [Abstract][Full Text] [Related]
11. Disease Modification in Parkinson's Disease: Current Approaches, Challenges, and Future Considerations. Lang AE; Espay AJ Mov Disord; 2018 May; 33(5):660-677. PubMed ID: 29644751 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of animal models of Parkinson's disease for neuroprotective strategies. Emborg ME J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225 [TBL] [Abstract][Full Text] [Related]
19. The role of nonhuman primate models in the development of cell-based therapies for Parkinson's disease. Vermilyea SC; Emborg ME J Neural Transm (Vienna); 2018 Mar; 125(3):365-384. PubMed ID: 28326445 [TBL] [Abstract][Full Text] [Related]
20. The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future. Fox SH; Brotchie JM Prog Brain Res; 2010; 184():133-57. PubMed ID: 20887873 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]